Ambalal Sarabhai Enterprises
37.89
-1.65(-4.17%)
Market Cap₹290.36 Cr
PE Ratio22.32
IndustryHealthcare
Company Performance:
1D-4.17%
1M-13.91%
6M+16.76%
1Y+16.76%
5Y+16.76%
View Company Insightsright
More news about Ambalal Sarabhai Enterprises
14May 26
Ambalal Sarabhai Enterprises Board Meeting Scheduled for May 21, 2026 to Approve FY26 Financial Results
Ambalal Sarabhai Enterprises has notified BSE Limited of a Board of Directors meeting to be held on May 21, 2026, pursuant to Regulation 29 of SEBI (LODR) Regulations, 2015. The meeting will consider approval of Audited Financial Results (Standalone & Consolidated) for the quarter and year ended March 31, 2026, along with the Auditors' Report. The board will also fix the date for the ensuing Annual General Meeting and the Book Closure date. The trading window for the company's securities remains closed from April 01, 2026 to May 23, 2026, both days inclusive.
 no imag found
10Apr 26
Ambalal Sarabhai Enterprises Submits SEBI Compliance Certificate for March 2026 Quarter
Ambalal Sarabhai Enterprises Limited submitted a compliance certificate to BSE under SEBI Regulation 74(5) for the quarter ended March 31, 2026. The certificate, filed on April 9, 2026, confirms proper handling of dematerialization processes by registrar MCS Share Transfer Agent Limited. The submission demonstrates regulatory compliance and proper corporate governance practices in securities handling and depository operations.
 no imag found
13Nov 25
Ambalal Sarabhai Enterprises Reports Q2 Loss Despite Revenue Stability
Ambalal Sarabhai Enterprises Limited (ASE) reported mixed Q2 results with a 0.57% decrease in revenue to Rs 4,444.92 lakhs and a net loss of Rs 56.03 lakhs, down 121.39% year-over-year. The Electronics segment remained profitable with Rs 213.37 lakhs in segment results, while Pharmaceuticals reported a loss of Rs 121.14 lakhs. Half-year revenue reached Rs 8,478.80 lakhs with a net profit of Rs 766.32 lakhs. Total assets stood at Rs 26,019.34 lakhs with total equity of Rs 13,752.35 lakhs as of September 30.
 no imag found
06Nov 25
Ambalal Sarabhai Enterprises' Joint Venture CoSara Diagnostics Explores SPAC Merger
CoSara Diagnostics, a joint venture of Ambalal Sarabhai Enterprises (ASE), is exploring strategic options. Co-Diagnostics Inc., ASE's partner, has engaged Maxim Group LLC to investigate possibilities such as a SPAC merger or listing on a U.S. national securities exchange. This move aims to unlock value for CoSara and its shareholders. CoSara, established in 2017, is a partnership between Co-Diagnostics Inc. and Synbiotics Ltd., focusing on molecular diagnostics products for international markets, particularly India.
 no imag found
27Oct 25
Ambalal Sarabhai's Telerad Division Clinches Top Broadcast Award at Industry Show
Ambalal Sarabhai Enterprises Limited's Telerad division, operating under Systronics India Limited, has been awarded the 'Best Regional Distributor — Broadcast - West Award' at the Broadcast India Show 2025 in Mumbai. Telerad, a leading system integrator in the broadcast industry, is recognized for providing comprehensive end-to-end solutions across various broadcast segments. This award highlights Telerad's leadership in innovative broadcast solutions and its strong presence in western India.
 no imag found
13Aug 25
Ambalal Sarabhai Enterprises Reports Stellar Q1 Performance with 2270% Profit Surge
Ambalal Sarabhai Enterprises (ASE) reported a consolidated net profit of Rs. 822.35 lakhs for Q1, a 2270% increase from Rs. 34.71 lakhs in the same quarter last year. Revenue from operations slightly decreased by 0.88% to Rs. 4,033.88 lakhs. The company's pharmaceuticals segment generated Rs. 2,546.42 lakhs, while electronics contributed Rs. 1,487.46 lakhs. On a standalone basis, profit after tax grew by 1391% to Rs. 690.85 lakhs. ASE's Board of Directors formed a new Pharma Committee to oversee pharmaceutical operations, compliance, and business performance.
 no imag found
1 Year Returns:+16.76%
Industry Peers
Sun Pharmaceutical
1,801.00
(-0.86%)
Divis Laboratories
9,249.00
(-0.46%)
Torrent Pharmaceuticals
4,767.30
(-0.68%)
Zydus Life Science
1,145.70
(-1.40%)
Cipla
1,344.00
(-0.15%)
Laurus Labs
1,984.00
(+0.20%)
Mankind Pharma
2,535.00
(+1.25%)
Dr Reddys Laboratories
1,206.20
(-2.17%)
Aurobindo Pharma
1,676.80
(+0.29%)
Lupin
2,031.20
(+0.05%)